Document is current
Any future updates will be listed below
-
Authors
Rotbauer, Martin
Dawe, Melanie
Nixon, Kevin C. J.
Tsao, Julissa
Durbic, Tanja
Sharma, Monika
Liang, Sheng-Ben
Zhang, Jie
Gopal, Nakita E. K.
Mrkonjic, Miralem
Alshamlan, Najd
Karavelic, Adnan
Murray, Ciara
Cescon, David W.
Bedard, Philippe L.
Done, Susan J. https://orcid.org/0000-0002-1770-988X
-
Funding
Funding for this research was provided by:
Canada Graduate Scholarships Masters
Cancer Research Society (summer internship award)
Canadian Institutes of Health Research (162282)
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 22 November 2025
First Online: 15 December 2025
Competing interests
: DWC reports consultancy and advisory relationships with AstraZeneca, Daiichi Sankyo, Exact Sciences, GenomeRx, Gilead, GlaxoSmithKline, Inivata/NeoGenomics, Lilly, Merck, Novartis, Pfizer, Roche and SAGA; research funding to their institution from AstraZeneca, GenomeRx, Guardant Health, Grail, Gilead, GlaxoSmithKline, Inivata/NeoGenomics, Knight, Merck, PearBio, Pfizer, ProteinQure, RayzeBio and Roche. PLB reports consultancy and advisory relationships with Bayer and Daiichi Sankyo; research funding to their institution from Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, GlaxoSmithKline, Novartis, Merck, Seattle Genetics, Lilly, Amgen, Bicara, Zymeworks, Medicenna, Bayer, Takeda, Gilead Sciences, LegoChem Biosciences, Boehringer Ingelheim, ProteinQure and Daiichi Sankyo/UCB Japan. No disclosures were reported by the other authors..
